Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2005

View Archived Issues

XTLbio signs license and asset purchase agreement with VivoQuest

Health Canada clearance for phase IIb study of AeroLEF for acute pain

Phase II data on the effects of Bronchitol in cystic fibrosis

CADA - a potential anti-HIV CD4-targeting microbicide

Preclinical data on seliciclib activity against MCL cell lines

Spotlight on pregabalin from the 11th World Congress on Pain

Good phase I results reported for oral RSD-1235 in healthy subjects

An herbal drug reported effective in the treatment of IAR

sanofi-aventis presents round-up of recent events

Clinical data on lenalidomide in CRPS type 1 patients

More evidence required for diagnosis of metabolic syndrome

Biken receives Japanese approval for combined measles-rubella vaccine

Approvable letter for Dacogen for myelodysplastic syndromes

Astex establishes new drug discovery collaboration with Boehringer Ingelheim

FDA advisory committee to consider abatacept infection, malignancy risk

Amgen to study darbepoetin alfa in treating anemia in heart failure patients

SkyePharma in negotiations over Flutiform

Roche seeks European approval for MabThera in rheumatoid arthritis

Immunomodulatory effects reported for ES-62 in a preclinical model of asthma

Phase I data on the effects of SB-485232 in renal cell carcinoma and multiple myeloma

Fondaparinux reported effective in the treatment of acute coronary syndromes

Novel agents for diabetes and related complications reported in recent patent literature

AEG-33690 will enter clinical testing for chemotherapy-induced neuropathy

Novel agents for alopecia claimed by Pfizer

Novel anti-HIV agents reported by Shionogi and AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...